{"id":3686,"date":"2022-04-26T06:56:17","date_gmt":"2022-04-26T06:56:17","guid":{"rendered":"https:\/\/aceoncology.org\/?p=3686"},"modified":"2022-04-26T06:56:18","modified_gmt":"2022-04-26T06:56:18","slug":"fda-new-cancer-indications-approvals-in-first-quarter-2022","status":"publish","type":"post","link":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/","title":{"rendered":"2022\u5e74\u7b2c1\u5b63\u5ea6FDA\u6279\u51c6\u7684\u80bf\u7624\u6cbb\u7597"},"content":{"rendered":"\n<p>2022\u5e74\u7b2c1\u5b63\u5ea6\uff0cFDA\u5171\u6279\u51c6\u4e867\u9879\u65b0\u7684\u80bf\u7624\u6cbb\u7597\u9002\u5e94\u75c7\uff1b3\u6708\u4efd\u7684\u6279\u51c6\u6570\u91cf\u63a5\u8fd1\u5386\u53f2\u8bb0\u5f55\uff0c\u5171\u67095\u9879\u9002\u5e94\u75c7\u83b7\u6279\u3002<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>\u65b0\u578b\u9776\u5411<\/strong><strong>PSMA<\/strong><strong>\u653e\u5c04\u6027\u914d\u4f53\u7528\u4e8e\u8f6c\u79fb\u6027\u53bb\u52bf\u62b5\u6297\u6027\u524d\u5217\u817a\u764c\u3002<\/strong>Lutetium\uff08Lu\uff09-177 vipivotide tetraxetan \uff08\u5546\u54c1\u540dPluvicto\u2122, \u7f8e\u56fdAdvanced Accelerator Applications\u516c\u53f8\uff09\u83b7\u6279\u7528\u4e8e\u6cbb\u7597\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u8fc7\u4e00\u79cd\u96c4\u6fc0\u7d20\u53d7\u4f53\uff08AR\uff09\u901a\u8def\u6291\u5236\u5242\u8054\u5408\u4e00\u79cd\u6216\u4e24\u79cd\u7d2b\u6749\u7c7b\u5316\u7597\u7684\u524d\u5217\u817a\u7279\u5f02\u6027\u819c\u6297\u539f\uff08PSMA\uff09\u9633\u6027\u8f6c\u79fb\u6027\u53bb\u52bf\u62b5\u6297\u6027\u524d\u5217\u817a\u764c\uff08mCRPC\uff09\u6210\u4eba\u60a3\u8005\u3002\u8be5\u6279\u51c6\u662f\u57fa\u4e8eIII\u671f\u3001\u591a\u4e2d\u5fc3\u3001\u5f00\u653e\u6027<a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/nejmoa2107322\">VISION<\/a>\u7814\u7a76\uff08n = 831\uff09\u7684\u7ed3\u679c\uff0c\u8be5\u7814\u7a76\u5c06\u8fdb\u5c55\u6027\u3001PSMA\u9633\u6027mCRPC\u60a3\u8005\u968f\u673a\u5206\u914d\u81f3\u6700\u4f73\u6807\u51c6\u6cbb\u7597\uff08BSoC\uff09\u5355\u836f\u6cbb\u7597\u7ec4\u6216Lu 177 vipivotide tetraxetan\u6cbb\u7597\u7ec4\u3002\u6b64\u5916\uff0c\u6240\u6709\u60a3\u8005\u5747\u63a5\u53d7\u4e86\u96c4\u6fc0\u7d20\u53bb\u52bf\u6cbb\u7597\u3002\u7814\u7a76\u8005\u89c2\u5bdf\u5230\u4e2d\u4f4d\u603b\u751f\u5b58\u671f\uff08OS\uff1b15.3 vs. 11.3\u4e2a\u6708\uff1b\u98ce\u9669\u6bd4[HR]=0.62\uff1bP &lt; 0.001\uff09\u548c\u4e2d\u4f4d\u5f71\u50cf\u5b66\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08rPFS\uff1b8.7 vs. 3.4\u4e2a\u6708\uff1bHR=0.4\uff1bP &lt; 0.001\uff09\u7edf\u8ba1\u5b66\u663e\u8457\u6539\u5584\u3002FDA\u540c\u65f6\u6279\u51c6\u4e86\u4e00\u79cd\u7528\u4e8e\u5236\u5907\u9553 68 gozetotide\uff08\u5546\u54c1\u540dLocametz\u00ae\uff0c\u8bfa\u534e\u516c\u53f8\uff09\u7684\u8bd5\u5242\u76d2\uff0c\u8fd9\u662f\u4e00\u79cd\u7528\u4e8ePSMA\u9633\u6027\u75c5\u7076\u6b63\u7535\u5b50\u53d1\u5c04\u65ad\u5c42\u626b\u63cf\uff08PET\uff09\u7684\u653e\u5c04\u6027\u8bca\u65ad\u8bd5\u5242\uff0c\u7528\u4e8e\u8bc6\u522b\u9002\u5408\u63a5\u53d7Lu 177 vipivotide tetraxetan\u6cbb\u7597\u7684\u60a3\u8005\u3002<\/li><\/ul>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>\u5e15\u535a\u5229\u73e0\u5355\u6297\u7528\u4e8e<\/strong><strong>MSI-H\/dMMR<\/strong><strong>\u665a\u671f\u5b50\u5bab\u5185\u819c\u764c\u3002<\/strong>\u5e15\u535a\u5229\u73e0\u5355\u6297\uff08\u53ef\u745e\u8fbe\u00ae\uff0c\u9ed8\u6c99\u4e1c\uff09\u5355\u836f\u83b7\u6279\u7528\u4e8e\u6cbb\u7597\u65e2\u5f80\u63a5\u53d7\u8fc7\u4efb\u4f55\u5168\u8eab\u6cbb\u7597\u540e\u8fdb\u5c55\u4e14\u4e0d\u9002\u5408\u6839\u6cbb\u6027\u624b\u672f\u6216\u653e\u7597\u7684\u5fae\u536b\u661f\u9ad8\u5ea6\u4e0d\u7a33\u5b9a\uff08MSI-H\uff09\u6216\u9519\u914d\u4fee\u590d\u7f3a\u9677\uff08dMMR\uff09\u665a\u671f\u5b50\u5bab\u5185\u819c\u764c\u60a3\u8005\u3002MSI-H\u6216dMMR\u72b6\u6001\u5fc5\u987b\u7531FDA\u6279\u51c6\u7684\u68c0\u6d4b\u786e\u5b9a\u3002\u8be5\u6279\u51c6\u662f\u57fa\u4e8e\u4e00\u9879\u591a\u4e2d\u5fc3\u3001\u975e\u968f\u673a\u3001\u5f00\u653e\u6027\u7814\u7a76<a href=\"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.21.01874\">KEYNOTE-158<\/a>\u7684\u7597\u6548\u7ed3\u679c\uff0c\u8be5\u7814\u7a76\u7eb3\u5165\u4e86\u65e2\u5f80\u63a5\u53d7\u8fc7\u6cbb\u7597\u7684\u665a\u671fMSI-H\/dMMR\u80bf\u7624\u60a3\u8005\uff0c\u5305\u62ec90\u4f8b\u5b50\u5bab\u5185\u819c\u764c\u60a3\u8005\uff08\u961f\u5217D\u548cK\uff09\u3002\u4e3b\u8981\u7597\u6548\u7ed3\u5c40\u6307\u6807\u4e3a\u76f2\u6001\u72ec\u7acb\u8bc4\u5ba1\u59d4\u5458\u4f1a\uff08BICR\uff09\u8bc4\u4f30\u7684\u5ba2\u89c2\u7f13\u89e3\u7387\uff08ORR\uff09\u548c\u6301\u7eed\u7f13\u89e3\u65f6\u95f4\uff08DoR\uff09\u3002ORR\u4e3a46%\uff0c\u672a\u8fbe\u5230\u4e2d\u4f4dDoR\uff0c68%\u60a3\u8005\u7684\u6301\u7eed\u7f13\u89e3\u65f6\u95f4\u226512\u4e2a\u6708\uff0c44%\u60a3\u8005\u6301\u7eed\u7f13\u89e3\u65f6\u95f4\u226524\u4e2a\u6708\u3002<\/li><\/ul>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>LAG-3<\/strong><strong>\u548c<\/strong><strong>PD-1<\/strong><strong>\u53cc\u91cd\u68c0\u67e5\u70b9\u6291\u5236\u5242\u7528\u4e8e\u4e0d\u53ef\u5207\u9664\u6216\u8f6c\u79fb\u6027\u9ed1\u8272\u7d20\u7624\u3002<\/strong>\u7eb3\u6b66\u5229\u5c24\u5355\u6297\u548crelatlimab\uff08\u5546\u54c1\u540dOpdualag\u2122,\u767e\u65f6\u7f8e\u65bd\u8d35\u5b9d\u516c\u53f8\uff09\u7684\u8054\u5408\u7528\u836f\u83b7\u6279\u7528\u4e8e\u4e0d\u53ef\u5207\u9664\u6216\u8f6c\u79fb\u6027\u9ed1\u8272\u7d20\u7624\u7684\u6210\u4eba\u548c\u513f\u7ae5\u60a3\u8005\uff0812\u5c81\u53ca\u4ee5\u4e0a\uff09\u3002\u8be5\u7ec4\u5408\u5305\u62ec\u56fa\u5b9a\u5242\u91cf\u7684LAG-3\u6291\u5236\u5242relatlimab\uff08160 mg\uff09\u548cPD-1\u6291\u5236\u5242\u7eb3\u6b66\u5229\u5c24\u5355\u6297\uff08480 mg\uff09\u3002\u8be5\u6279\u51c6\u57fa\u4e8e<a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2109970\">RELATIVITY-047<\/a>\u7814\u7a76\uff0c\u8fd9\u662f\u4e00\u9879\u53cc\u76f2\u3001II\u2013III\u671f\u7814\u7a76\uff0c\u5165\u7ec4\u7684714\u4f8b\u65e2\u5f80\u672a\u7ecf\u6cbb\u7597\u7684\u8f6c\u79fb\u6027\u6216\u4e0d\u53ef\u5207\u9664\u7684III\u671f\u6216IV\u671f\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u968f\u673a\u63a5\u53d7\u7eb3\u6b66\u5229\u5c24\u5355\u6297\u548crelatlimab \u8054\u5408\u6cbb\u7597\u6216\u7eb3\u6b66\u5229\u5c24\u5355\u6297\u5355\u836f\u6cbb\u7597\u3002\u4e0e\u7eb3\u6b66\u5229\u5c24\u5355\u6297\u5355\u836f\u6cbb\u7597\u76f8\u6bd4\uff0c\u8054\u5408\u6cbb\u7597\u663e\u793a\u51fa\u66f4\u5927\u7684\u4e2d\u4f4dPFS\u83b7\u76ca\uff08\u4e3b\u8981\u7814\u7a76\u7ec8\u70b9\uff09\uff0810.1 vs. 4.6\u4e2a\u6708\uff1bHR=0.75\uff1bP = 0.0055\uff09\u3002OS\u65e0\u7edf\u8ba1\u5b66\u610f\u4e49\uff08HR=0.80\uff1bP = 1.01\uff09\uff0c\u8054\u5408\u6cbb\u7597\u7ec4\u672a\u8fbe\u5230\u4e2d\u4f4dOS\uff0c\u7eb3\u6b66\u5229\u5c24\u5355\u6297\u7ec4\u4e3a34.1\u4e2a\u6708\u3002<\/li><\/ul>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>\u53cc\u7279\u5f02\u6027\u878d\u5408\u86cb\u767dTebentafusp<\/strong><strong>\u7528\u4e8e\u4e0d\u53ef\u5207\u9664\u6216\u8f6c\u79fb\u6027\u8461\u8404\u819c\u9ed1\u8272\u7d20\u7624\u3002<\/strong>tebentafusp-tebn\uff08\u5546\u54c1\u540dKimmtrak\u00ae,Immunocore Limited\u516c\u53f8\uff09\u662f\u4e00\u79cd\u53cc\u7279\u5f02\u6027gp100\u80bd-HLA\u5b9a\u5411CD3 T\u7ec6\u80de\u8854\u63a5\u7cfb\u7edf\uff0c\u83b7\u6279\u7528\u4e8e\u6cbb\u7597HLA-a*02:01\u9633\u6027\u7684\u4e0d\u53ef\u5207\u9664\u6216\u8f6c\u79fb\u6027\u8461\u8404\u819c\u9ed1\u8272\u7d20\u7624\u6210\u4eba\u60a3\u8005\u3002\u8be5\u6279\u51c6\u57fa\u4e8e<a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2103485\">IMCgp100-202<\/a>\u7684\u7597\u6548\u7ed3\u679c\uff0cIMCgp100-202\u662f\u4e00\u9879\u5728378\u4f8b\u8f6c\u79fb\u6027\u8461\u8404\u819c\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u4e2d\u5f00\u5c55\u7684\u968f\u673a\u3001III\u671f\u3001\u5f00\u653e\u6807\u7b7e\u3001\u591a\u4e2d\u5fc3\u7814\u7a76\u3002\u5165\u7ec4\u60a3\u8005\u4e3a\u4e2d\u5fc3\u5b9e\u9a8c\u5ba4\u68c0\u6d4b\u786e\u5b9a\u7684HLA-A*02:01\u57fa\u56e0\u578b\u9633\u6027\u60a3\u8005\u3002\u65e2\u5f80\u63a5\u53d7\u8fc7\u5168\u8eab\u6cbb\u7597\u6216\u809d\u810f\u5c40\u90e8\u6cbb\u7597\u7684\u60a3\u8005\u88ab\u6392\u9664\uff1b\u4f46\u662f\uff0c\u5141\u8bb8\u65e2\u5f80\u624b\u672f\u5207\u9664\u5be1\u8f6c\u79fb\u6027\u75be\u75c5\u60a3\u8005\u3002\u60a3\u8005\u968f\u673a\u63a5\u53d7tebentafusp\u6216\u7814\u7a76\u8005\u9009\u62e9\u7684\u5e15\u535a\u5229\u73e0\u5355\u6297\u3001\u4f0a\u5339\u6728\u5355\u6297\u6216\u8fbe\u5361\u5df4\u55ea\u6cbb\u7597\u3002tebentafusp\u6cbb\u7597\u7ec4\u7684OS\u957f\u4e8e\u7814\u7a76\u8005\u9009\u62e9\u6cbb\u7597\u7ec4\uff0821.7 vs. 16\u4e2a\u6708\uff1bHR=0.51\uff1bP &lt; 0.0001\uff09\u3002<\/li><\/ul>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>\u5965\u62c9\u5e15\u5229\u7528\u4e8e\u65e9\u671f\u9ad8\u5371\u4e73\u817a\u764c\u7684\u8f85\u52a9\u6cbb\u7597\u3002<\/strong>\u5965\u62c9\u5e15\u5229\uff08\u5229\u666e\u5353\u00ae\uff0c\u963f\u65af\u5229\u5eb7\uff09\u7528\u4e8e\u4e73\u817a\u764c\u7684\u9002\u5e94\u75c7\u5df2\u6269\u5c55\u81f3\u8f85\u52a9\u6cbb\u7597\u6709\u5bb3\u6216\u7591\u4f3c\u6709\u5bb3\u7684\u751f\u6b96\u7cfbBRCA\u7a81\u53d8\uff08gBRCAm\uff09\u3001HER2\u9634\u6027\u3001\u9ad8\u5371\u65e9\u671f\u4e73\u817a\u764c\u60a3\u8005\uff0c\u8fd9\u4e9b\u60a3\u8005\u5df2\u63a5\u53d7\u8fc7\u65b0\u8f85\u52a9\u6216\u8f85\u52a9\u5316\u7597\u3002\u4e34\u5e8a\u533b\u751f\u5fc5\u987b\u4f7f\u7528FDA\u6279\u51c6\u7684\u5965\u62c9\u5e15\u5229\u4f34\u968f\u8bca\u65ad\u6765\u9009\u62e9\u60a3\u8005\u8fdb\u884c\u6cbb\u7597\u3002\u6b64\u6b21\u6279\u51c6\u662f\u57fa\u4e8e\u4e00\u9879III\u671f\u3001\u53cc\u76f2\u3001\u5b89\u6170\u5242\u5bf9\u7167\u3001\u56fd\u9645<a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2105215\">OlympiA\u7814\u7a76<\/a>\uff0c\u8be5\u7814\u7a76\u7eb3\u5165\u4e861836\u4f8bgBRCA\u7a81\u53d8\u3001HER2\u9634\u6027\u3001\u65e9\u671f\u9ad8\u5371\u4e73\u817a\u764c\u60a3\u8005\uff0c\u8fd9\u4e9b\u60a3\u8005\u5b8c\u6210\u4e86\u6839\u6cbb\u6027\u5c40\u90e8\u6cbb\u7597\u548c\u65b0\u8f85\u52a9\u6216\u8f85\u52a9\u5316\u7597\uff08\u4ee5\u84bd\u73af\u7c7b\/\u7d2b\u6749\u70f7\u4e3a\u57fa\u7840\uff09\uff0c\u968f\u673a\u63a5\u53d7\u4e3a\u671f1\u5e74\u7684\u5965\u62c9\u5e15\u5229\u6216\u5b89\u6170\u5242\u6cbb\u7597\u3002OlympiA\u7684\u4e3b\u8981\u7597\u6548\u7ec8\u70b9\u662f\u65e0\u4fb5\u88ad\u6027\u75be\u75c5\u751f\u5b58\u671f\uff08IDFS\uff09\u3002\u63a5\u53d7\u5965\u62c9\u5e15\u5229\u6cbb\u7597\u7684\u60a3\u80053\u5e74IDFS\u4e3a86%\uff0c\u63a5\u53d7\u5b89\u6170\u5242\u6cbb\u7597\u7684\u60a3\u8005\u4e3a77%\uff08HR=0.58\uff1bP &lt; 0.0001\uff09\u3002\u6b64\u5916\uff0c\u5965\u62c9\u5e15\u5229\u7ec4\u62a5\u544a\u7684\u6b7b\u4ea1\u4f8b\u6570\u5c11\u4e8e\u5b89\u6170\u5242\u7ec4\uff0875\u4f8b [8%] vs. 109\u4f8b [12%]\uff09\uff0c\u4e14\u6839\u636e<a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-adjuvant-treatment-high-risk-early-breast-cancer\">FDA\u62a5\u544a<\/a>\u8be5\u5dee\u5f02\u5177\u6709\u7edf\u8ba1\u5b66\u610f\u4e49\uff08HR=0.68\uff0cP = 0.0091\uff09\u3002<\/li><\/ul>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>\u7eb3\u6b66\u5229\u5c24\u5355\u6297\u8054\u5408\u542b\u94c2\u53cc\u836f\u5316\u7597\u7528\u4e8e\u65e9\u671f\u80ba\u764c\u7684\u65b0\u8f85\u52a9\u6cbb\u7597\u3002<\/strong>FDA\u6279\u51c6\u7eb3\u6b66\u5229\u5c24\u5355\u6297\uff08\u6b27\u72c4\u6c83\u00ae\uff0c\u767e\u65f6\u7f8e\u65bd\u8d35\u5b9d\uff09\u8054\u5408\u542b\u94c2\u53cc\u836f\u5316\u7597\u7528\u4e8e\u53ef\u5207\u9664\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC\uff09\u60a3\u8005\u7684\u65b0\u8f85\u52a9\u6cbb\u7597\uff0c\u8fd9\u662f\u9996\u4e2a\u83b7\u6279\u7684\u65e9\u671f\u80ba\u764c\u65b0\u8f85\u52a9\u6cbb\u7597\u7684\u9002\u5e94\u75c7\u3002\u8be5\u6279\u51c6\u57fa\u4e8e\u4e00\u9879III\u671f\u3001\u5f00\u653e\u6807\u7b7e<a href=\"https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2202170\">CHECKMATE-816\u7814\u7a76<\/a>\u7684\u7597\u6548\u7ed3\u679c\uff0c\u8be5\u7814\u7a76\u5c06358\u4f8b\u7ecf\u7ec4\u7ec7\u5b66\u8bc1\u5b9e\u7684\u53ef\u5207\u9664IB\u671f\uff08\u22654 cm\uff09-IIIA\u671fNSCLC\u60a3\u8005\u968f\u673a\u5206\u914d\u81f3\u63a5\u53d7\u7eb3\u6b66\u5229\u5c24\u5355\u6297\u8054\u5408\u542b\u94c2\u53cc\u836f\u5316\u7597\u6216\u5355\u72ec\u542b\u94c2\u5316\u7597\u3002\u4e0d\u8003\u8651\u60a3\u8005\u5165\u7ec4\u65f6\u80bf\u7624PD-L1\u72b6\u6001\u3002\u4e3b\u8981\u7ec8\u70b9\u4e3a\u65e0\u4e8b\u4ef6\u751f\u5b58\u671f\uff08EFS\uff09\u548cBICR\u8bc4\u4f30\u7684\u75c5\u7406\u5b66\u5b8c\u5168\u7f13\u89e3\uff08pCR\uff09\u3002\u7eb3\u6b66\u5229\u5c24\u5355\u6297\u8054\u5408\u5316\u7597\u7ec4\u7684\u4e2d\u4f4dEFS\u4e3a31.6\u4e2a\u6708\uff0c\u5355\u72ec\u5316\u7597\u7ec4\u4e3a20.8\u4e2a\u6708\uff08HR=0.63\uff1bP = 0.0052\uff09\u3002\u7eb3\u6b66\u5229\u5c24\u5355\u6297\u8054\u5408\u5316\u7597\u7ec4\u7684pCR\u7387\u4e3a24%\uff0c\u5355\u7eaf\u5316\u7597\u7ec4\u4e3a2.2%\u3002<\/li><\/ul>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>\u65b0\u7684<\/strong><strong>CAR-T<\/strong><strong>\u7ec6\u80de\u7597\u6cd5\u7528\u4e8e\u590d\u53d1\u6027\u6216\u96be\u6cbb\u6027\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u3002<\/strong>B\u7ec6\u80de\u6210\u719f\u6297\u539f\u5b9a\u5411\u5d4c\u5408\u6297\u539f\u53d7\u4f53\uff08CAR\uff09T\u7ec6\u80de\u7597\u6cd5ciltacabtagene autoleucel\uff08\u5546\u54c1\u540dCARVYKTI\u2122\uff0cJanssen Biotech\u516c\u53f8\uff09\u83b7\u6279\u7528\u4e8e\u6cbb\u7597\u65e2\u5f80\u63a5\u53d7\u8fc74\u7ebf\u53ca\u4ee5\u4e0a\u6cbb\u7597\uff08\u5305\u62ec\u86cb\u767d\u9176\u4f53\u6291\u5236\u5242\uff0c\u514d\u75ab\u8c03\u8282\u5242\uff08IMiD\uff09\u548c\u6297CD38\u5355\u6297\u6cbb\u7597\uff09\u540e\u7684\u590d\u53d1\u6027\u6216\u96be\u6cbb\u6027\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff08MM\uff09\u60a3\u8005\u3002\u8be5\u6279\u51c6\u662f\u57fa\u4e8e\u4e00\u9879Ib\/II\u671f\u3001\u5f00\u653e\u6027\u3001\u591a\u4e2d\u5fc3<a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(21)00933-8\/fulltext\">CARTITUDE-1<\/a>\u7814\u7a76\u7684\u5b89\u5168\u6027\u548c\u7597\u6548\u7ed3\u679c\uff0c\u8be5\u7814\u7a76\u572897\u4f8b\u590d\u53d1\u6027\u6216\u96be\u6cbb\u6027\u3001\u65e2\u5f80\u63a5\u53d7\u8fc7\u5927\u91cf\u6cbb\u7597\u7684MM\u60a3\u8005\u4e2d\u8bc4\u4ef7\u4e86ciltacabtagene autoleucel\uff0c\u5176\u4e2d82%\u7684\u60a3\u8005\u63a5\u53d7\u8fc74\u79cd\u62164\u79cd\u4ee5\u4e0a\u9aa8\u9ad3\u7624\u6cbb\u7597\u3002\u4e3b\u8981\u7597\u6548\u7ec8\u70b9\u4e3aORR\u548cDoR\uff0c\u7531\u72ec\u7acb\u8bc4\u4f30\u59d4\u5458\u4f1a\u4f7f\u7528MM\u7684\u56fd\u9645\u7f13\u89e3\u6807\u51c6\u8fdb\u884c\u8bc4\u4f30\uff0cORR\u4e3a97.9%\uff0c\u572895\u4f8b\u7f13\u89e3\u60a3\u8005\u4e2d\uff0c\u4e2d\u4f4dDoR\u4e3a21.8\u4e2a\u6708\uff0c\u4e2d\u4f4d\u968f\u8bbf\u65f6\u95f4\u4e3a18\u4e2a\u6708\u3002\u5904\u65b9\u4fe1\u606f\u5305\u542b\u4ee5\u4e0b\u9ed1\u6846\u8b66\u544a\uff1a\u7ec6\u80de\u56e0\u5b50\u91ca\u653e\u7efc\u5408\u5f81\uff08CRS\uff09\u3001\u566c\u8840\u7ec6\u80de\u6027\u6dcb\u5df4\u7ec4\u7ec7\u7ec6\u80de\u589e\u751f\u75c7\/\u5de8\u566c\u7ec6\u80de\u6d3b\u5316\u7efc\u5408\u5f81\uff08HLH\/MAS\uff09\u3001\u514d\u75ab\u6548\u5e94\u7ec6\u80de\u76f8\u5173\u795e\u7ecf\u6bd2\u6027\u7efc\u5408\u5f81\uff08ICANS\uff09\u3001\u5e15\u91d1\u68ee\u7efc\u5408\u5f81\u548c\u5409\u5170-\u5df4\u96f7\u7efc\u5408\u5f81\u53ca\u5176\u76f8\u5173\u5e76\u53d1\u75c7\u4ee5\u53ca\u957f\u671f\u548c\/\u6216\u590d\u53d1\u6027\u8840\u7ec6\u80de\u51cf\u5c11\u75c7\uff0c\u6240\u6709\u8fd9\u4e9b\u90fd\u53ef\u80fd\u81f4\u547d\u6216\u5371\u53ca\u751f\u547d\u3002\u8fd9\u79cd\u6cbb\u7597\u53ea\u80fd\u5728\u7ecf\u8fc7\u4e13\u95e8\u8ba4\u8bc1\u7684\u533b\u9662\u8fdb\u884c\u3002<\/li><\/ul>\n","protected":false},"excerpt":{"rendered":"<p>2022\u5e74\u7b2c1\u5b63\u5ea6\uff0cFDA\u5171\u6279\u51c6\u4e867\u9879\u65b0\u7684\u80bf\u7624\u6cbb\u7597\u9002\u5e94\u75c7\uff1b3\u6708\u4efd\u7684\u6279\u51c6\u6570\u91cf\u63a5\u8fd1\u5386\u53f2\u8bb0\u5f55\uff0c\u5171\u67095\u9879\u9002\u5e94\u75c7\u83b7\u6279\u3002  [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":3684,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[42],"tags":[],"class_list":["post-3686","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-42"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>2022\u5e74\u7b2c1\u5b63\u5ea6FDA\u6279\u51c6\u7684\u80bf\u7624\u6cbb\u7597 - ACE Oncology<\/title>\n<meta name=\"description\" content=\"2022\u5e74\u7b2c1\u5b63\u5ea6\u7f8e\u56fdFDA\u6279\u51c67\u9879\u80bf\u7624\u6cbb\u7597\u65b0\u9002\u5e94\u75c7\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"2022\u5e74\u7b2c1\u5b63\u5ea6FDA\u6279\u51c6\u7684\u80bf\u7624\u6cbb\u7597 - ACE Oncology\" \/>\n<meta property=\"og:description\" content=\"2022\u5e74\u7b2c1\u5b63\u5ea6\u7f8e\u56fdFDA\u6279\u51c67\u9879\u80bf\u7624\u6cbb\u7597\u65b0\u9002\u5e94\u75c7\" \/>\n<meta property=\"og:url\" content=\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"ACE Oncology\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-26T06:56:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-26T06:56:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/04\/Picture-Blog-Post-38_New-Drug-Approvals_Middle-Size.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"526\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"ACE Demo\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:site\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ACE Demo\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/\"},\"author\":{\"name\":\"ACE Demo\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0\"},\"headline\":\"2022\u5e74\u7b2c1\u5b63\u5ea6FDA\u6279\u51c6\u7684\u80bf\u7624\u6cbb\u7597\",\"datePublished\":\"2022-04-26T06:56:17+00:00\",\"dateModified\":\"2022-04-26T06:56:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/\"},\"wordCount\":167,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/04\/Picture-Blog-Post-38_New-Drug-Approvals_Middle-Size.jpg\",\"articleSection\":[\"\u65b0\u836f\u83b7\u6279\"],\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/\",\"url\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/\",\"name\":\"2022\u5e74\u7b2c1\u5b63\u5ea6FDA\u6279\u51c6\u7684\u80bf\u7624\u6cbb\u7597 - ACE Oncology\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/04\/Picture-Blog-Post-38_New-Drug-Approvals_Middle-Size.jpg\",\"datePublished\":\"2022-04-26T06:56:17+00:00\",\"dateModified\":\"2022-04-26T06:56:18+00:00\",\"description\":\"2022\u5e74\u7b2c1\u5b63\u5ea6\u7f8e\u56fdFDA\u6279\u51c67\u9879\u80bf\u7624\u6cbb\u7597\u65b0\u9002\u5e94\u75c7\",\"breadcrumb\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/#primaryimage\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/04\/Picture-Blog-Post-38_New-Drug-Approvals_Middle-Size.jpg\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/04\/Picture-Blog-Post-38_New-Drug-Approvals_Middle-Size.jpg\",\"width\":1000,\"height\":526},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"ACE Oncology\",\"item\":\"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"2022\u5e74\u7b2c1\u5b63\u5ea6FDA\u6279\u51c6\u7684\u80bf\u7624\u6cbb\u7597\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/aceoncology.org\/#website\",\"url\":\"https:\/\/aceoncology.org\/\",\"name\":\"ACE Oncology\",\"description\":\"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.\",\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/aceoncology.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/aceoncology.org\/#organization\",\"name\":\"ACE Oncology\",\"url\":\"https:\/\/aceoncology.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"width\":156,\"height\":83,\"caption\":\"ACE Oncology\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/ace_oncology\",\"https:\/\/www.linkedin.com\/company\/aceoncology\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0\",\"name\":\"ACE Demo\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g\",\"caption\":\"ACE Demo\"},\"url\":\"https:\/\/aceoncology.org\/zh-hans\/author\/demo\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"2022\u5e74\u7b2c1\u5b63\u5ea6FDA\u6279\u51c6\u7684\u80bf\u7624\u6cbb\u7597 - ACE Oncology","description":"2022\u5e74\u7b2c1\u5b63\u5ea6\u7f8e\u56fdFDA\u6279\u51c67\u9879\u80bf\u7624\u6cbb\u7597\u65b0\u9002\u5e94\u75c7","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/","og_locale":"zh_CN","og_type":"article","og_title":"2022\u5e74\u7b2c1\u5b63\u5ea6FDA\u6279\u51c6\u7684\u80bf\u7624\u6cbb\u7597 - ACE Oncology","og_description":"2022\u5e74\u7b2c1\u5b63\u5ea6\u7f8e\u56fdFDA\u6279\u51c67\u9879\u80bf\u7624\u6cbb\u7597\u65b0\u9002\u5e94\u75c7","og_url":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/","og_site_name":"ACE Oncology","article_published_time":"2022-04-26T06:56:17+00:00","article_modified_time":"2022-04-26T06:56:18+00:00","og_image":[{"width":1000,"height":526,"url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/04\/Picture-Blog-Post-38_New-Drug-Approvals_Middle-Size.jpg","type":"image\/jpeg"}],"author":"ACE Demo","twitter_card":"summary_large_image","twitter_creator":"@ace_oncology","twitter_site":"@ace_oncology","twitter_misc":{"\u4f5c\u8005":"ACE Demo","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"1 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/#article","isPartOf":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/"},"author":{"name":"ACE Demo","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0"},"headline":"2022\u5e74\u7b2c1\u5b63\u5ea6FDA\u6279\u51c6\u7684\u80bf\u7624\u6cbb\u7597","datePublished":"2022-04-26T06:56:17+00:00","dateModified":"2022-04-26T06:56:18+00:00","mainEntityOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/"},"wordCount":167,"commentCount":0,"publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/04\/Picture-Blog-Post-38_New-Drug-Approvals_Middle-Size.jpg","articleSection":["\u65b0\u836f\u83b7\u6279"],"inLanguage":"zh-Hans","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/","url":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/","name":"2022\u5e74\u7b2c1\u5b63\u5ea6FDA\u6279\u51c6\u7684\u80bf\u7624\u6cbb\u7597 - ACE Oncology","isPartOf":{"@id":"https:\/\/aceoncology.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/#primaryimage"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/04\/Picture-Blog-Post-38_New-Drug-Approvals_Middle-Size.jpg","datePublished":"2022-04-26T06:56:17+00:00","dateModified":"2022-04-26T06:56:18+00:00","description":"2022\u5e74\u7b2c1\u5b63\u5ea6\u7f8e\u56fdFDA\u6279\u51c67\u9879\u80bf\u7624\u6cbb\u7597\u65b0\u9002\u5e94\u75c7","breadcrumb":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/#primaryimage","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/04\/Picture-Blog-Post-38_New-Drug-Approvals_Middle-Size.jpg","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/04\/Picture-Blog-Post-38_New-Drug-Approvals_Middle-Size.jpg","width":1000,"height":526},{"@type":"BreadcrumbList","@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-in-first-quarter-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"ACE Oncology","item":"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/"},{"@type":"ListItem","position":2,"name":"2022\u5e74\u7b2c1\u5b63\u5ea6FDA\u6279\u51c6\u7684\u80bf\u7624\u6cbb\u7597"}]},{"@type":"WebSite","@id":"https:\/\/aceoncology.org\/#website","url":"https:\/\/aceoncology.org\/","name":"ACE Oncology","description":"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.","publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/aceoncology.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/aceoncology.org\/#organization","name":"ACE Oncology","url":"https:\/\/aceoncology.org\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","width":156,"height":83,"caption":"ACE Oncology"},"image":{"@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ace_oncology","https:\/\/www.linkedin.com\/company\/aceoncology"]},{"@type":"Person","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0","name":"ACE Demo","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g","caption":"ACE Demo"},"url":"https:\/\/aceoncology.org\/zh-hans\/author\/demo\/"}]}},"_links":{"self":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/3686","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/comments?post=3686"}],"version-history":[{"count":1,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/3686\/revisions"}],"predecessor-version":[{"id":3687,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/3686\/revisions\/3687"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media\/3684"}],"wp:attachment":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media?parent=3686"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/categories?post=3686"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/tags?post=3686"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}